Market Access
Market Access Strategy. Evidence-Led Value. Sustainable Patient Access.
Market Access Strategy. Evidence-Led Value. Sustainable Patient Access.
Market Access plays a critical role in translating scientific innovation into meaningful value for healthcare systems, payers, clinicians, and patients. Successful access requires more than demonstrating clinical efficacy; it demands a clear understanding of the economic, clinical, and policy environments that influence reimbursement and adoption.
At Amodaia, we partner with biotech, pharmaceutical, and medical technology organisations to develop global, regional, and local market access strategies that connect clinical evidence, health economics, pricing considerations, and stakeholder expectations.
From early access planning and evidence gap assessment to value proposition development, HEOR strategy, HTA preparation, and payer engagement, we combine scientific understanding with commercial insight to help organisations demonstrate the value of their innovations.
Whether you need senior strategic advice, support navigating complex reimbursement environments, or specialist expertise to develop high-quality evidence and access materials, we tailor our involvement to your needs.
Our Services Include:
- Global, regional, and local market access strategy, and planning
- Early market access assessment, evidence gap analysis, and payer landscape evaluation
- HEOR strategy and evidence planning
- Pricing, reimbursement, and access pathway strategy
- Clinical and economic value proposition development
- HTA strategy, preparation, and submission support
- Cost-effectiveness, burden-of-illness, and real-world evidence communication
- Global value dossiers, AMCP dossiers, payer presentations, and objection-handling materials
- Payer advisory boards, stakeholder engagement, and cross-functional access workshops
Our Market Access approach combines strategic insight, scientific and economic expertise, and specialist execution to help organisations demonstrate value, navigate reimbursement challenges, and support informed access decisions across markets.
Our Narrative Integrity Framework™ can provide an additional layer of scrutiny, helping align clinical evidence, economic value, and payer-facing narratives.
Case Studies
Biotech | EU – Market Access Payer
Readiness for TED Biologic
Challenge: A global biologic programme approaching payer engagement equired a coherent market access position across clinical evidence, HEOR considerations, value communication, and regional HTA requirements.
Solution: Amodaia supported the development of an evidence-led value proposition, bringing together clinical and economic considerations to inform payer communications, stakeholder discussions, and regional access planning.
Challenge: A global biologic programme approaching payer engagement equired a coherent market access position across clinical evidence, HEOR considerations, value communication, and regional HTA requirements.
Solution: Amodaia supported the development of an evidence-led value proposition, bringing together clinical and economic considerations to inform payer communications, stakeholder discussions, and regional access planning.
Impact: A clearer, more consistent framework for communicating product value, identifying evidence requirements, and preparing for payer and HTA engagement across European markets.
